Abstract-Increased expression of the insulin like growth factor (IGF) family members, IGF1, IGF2, their receptors and binding proteins, or combinations thereof has been documented in various malignancies including gliomas. The results of multiple investigations suggest that the IGFs can play a paracrine and/or autocrine role in promoting tumor growth in situ during tumor progression but that these roles may vary depending on the tissue of origin. Enhanced IGF1 expression was not found in glioblastomas and it was sup posed that IGF1 participation in the development of glial tumors may be substituted by protein products of highly expressed other genes, also participating in PI3K and MAPK pathways. Increased expression of IGF binding protein genes in brain tumors makes the picture even more complicated. As other binding proteins, IGFBPs regulate the activity of their ligands by prolonging their half life. The discrepancies arising from con flicting evidence on the results obtained by different laboratories in human gliomas are discussed. Our data highlight the importance of viewing the IGF related proteins as a complex multifactorial system and show that changes in the expression levels of any one component of the system, in a given malignancy, should be interpreted with caution. As IGF targeting for anticancer therapy is rapidly becoming clinical reality, an understanding of this complexity is very timely.
INTRODUCTION
In recent years, evidences have been appearing that the members of IGF system may be involved in cancer development. The anti sense strategies, directed to the components of IGF signaling, are the subject of many clinical trials. All three IGF receptors (IGF1R, INSR and IGF2R) are very well known targets for anti cancer therapy. Increased expression of IGF1 receptor same as its ligands may stimulate PI3K and MAPK signaling cascades leading to cell proliferation [1] [2] [3] .
However, the role of IGFs, IGF receptors and IGF binding proteins (IGFBPs) in tumor develop ment is poorly understood to this time. Increased lev els of IGF1, IGF2 and their receptors have been found in different tumor types (reviewed in [4] ), although the data about IGF1 and IGF2 gene expression in astro cytic gliomas are quite ambiguous. There are several publications reporting enhanced expression of these genes in anaplastic astrocytomas and glioblastomas on the RNA or protein levels [5] [6] [7] [8] . For example, Sand berg et al. [5] analysed the expression of IGF genes by slot blot and Northern blot hybridization and found several fold increased IGF1 and IGF2 mRNA levels in 1 The article is published in the original. one anaplastic astrocytoma and three glioblastoma specimens analyzed as compared to different regions of human adult normal brain. In other work, these authors demonstrated by immunohistochemistry the production of IGF1 like peptide in tumor cells in two of three anaplastic astrocytomas and in three of four glioblastomas examined [6] . In situ hybridization and immunocytochem istry also have localized a produc tion of both IGF1 and IGF2 mRNA and protein in small number of astrocytoma samples analyzed that was accompanied by the co expression of respective type 1 and type 2 IGF receptors [7] . Immunocy tochemical analysis of 39 astrocytic tumors of WHO grades II-IV revealed tumor cells expressing IGF1 and IGF1R in all tumor grades (however, authors do not show how many of samples being under investiga tion were positive) [8] .
On the other hand, the expression of IGF1 and IGF2 genes in astrocytic tumors was not found in other investigations. Thus, IGF2 mRNA was not detected by Northern analysis in 5 astrocytomas and 2 glioblasto mas [9] , and the expression of lGF1 was not found by Northern analysis in two investigated gliomas (ependymoma and glioblastoma) [10] . Earlier, we also could not find the significant change of IGF1 gene expression in glioblastoma by Serial Analysis of Gene Expression (SAGE) [11] . Such contradictory results
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could be explained by not enough big quantity of sam ples being under investigations. Nevertheless, IGF1 and IGF2 genes were not presented also in the lists of the genes with significant expression changes in the articles on integrative genome wide analysis of 81 [12] and 460 glioblastoma samples [13] . Expression of insulin like growth factor binding protein (IGFBP) genes in brain tumors makes the pic ture even more complicated. The IGFBP family con sists of six high affinity members (IGFBP1-IGFBP6) and four low affinity proteins (IGFBP7-IGFBP10) which contain on the NH 2 termini con served "IGFBP motif" (GCGC CXXC), share signif icant structural homology with IGFBP1-IGFBP6, and able specifically bind IGFs, although with rela tively low affinity [14] . As other binding proteins, IGFBPs regulate the activity of their ligands by pro longing their half life. The biological actions of IGFs may be regulated by IGFBPs either negatively or pos itively, depending on the tissue type and the physiolog ical or pathological status, some of the IGFBPs also act by a mechanism independent of IGFs. Elevation of the activity of IGF1 and IGF2 in the absence of the increasing of their genes expression may be a result of the enhancement of stability and lifetime due to the interaction with IGFBPs [15] . In addition to func tioning in extracellular fluids as simple carrier proteins regulating circulating IGF turnover, transport, and distribution, the locally produced IGFBPs act as auto crine/paracrine regulators of IGF action [16] .
Here, we analyze the expression of IGF system members including all ten IGFBP genes in glioblas toma by different methods to clarify their expression patterns in this tumor.
MATERIALS AND METHODS
SAGE Genie database (http://cgap.nci.nih.gov/ SAGE) was used for the comparison of gene expres sion in glioblastoma and human normal brain by Dig ital Gene Expression Displayer (DGED) tool. Two pools of SAGE libraries (9 libraries of glioblastoma and 5 normal adult human brain libraries) were com pared. Data, obtained by microarray analysis and available in Gene Expression Omnibus (GEO) site (http://www.ncbi.nlm. nih.gov/geo), were used also for the comparison of these genes expression in glial tumors and normal brain. DataSet files were searched by keywords "glioblastoma," "astrocy toma," and "normal brain." A DataSet represents a collection of biologically and statistically comparable samples processed using the same platform. In order to mea sure expression levels from different DataSet files accurately, normalization by several housekeeping genes was required. Scripts, written in Perl were used for the analysis of these data.
Glioblastoma surgical specimens were classified on the basis of examination of hematoxylin and eosin stained sections according to World Health Organiza tion (WHO) criteria [17] . Surgical specimens of histo logically normal brain tissue adjacent to tumors were used as a source of normal adult human brain RNA and protein. All patients were being treated at the hos pital of A.P. Romodanov Institute of Neurosurgery (Kyiv, Ukraine). The study protocol was approved by the human ethics review committees of both institu tions and a signed consent forms from patients were obtained. The tissue samples were stored at -70°C until analysis. RNA was extracted from frozen samples as described in our previous articles [11, 18] .
Equal amounts of total cellular RNA (5 μg each for 20 μl mixture) were transcribed into cDNA with an oligo (dT)/random hexamer primers and Revert Aid M MuLV reverse transcriptase ("Fermentas", Lithua nia). Each semi quantitative RT PCR was performed in 25 μl reaction mixture containing cDNA synthe sized on 50 ng of RNA (2 μl of 10 fold diluted cDNA), 2U Dream Taq Green DNA polymerase (("Fermen tas", Lithuania), manufacturer's buffer, 0.2 mM dNTPs, and 10 μM gene specific primers (Table 1) . Thermal cycling parameters were: initial denaturing step at 95°C for 2 min, followed by 27-35 cycles of denatura tion at 95°C for 30 sec, annealing at 56°C for 30 sec, synthesis at 72°C for 30 sec, and final extension incubation at 72°C for 7 min. The number of cycles was chosen so that the PCR product amplification rate was in the linear phase. Amplified products were elec trophoresed in a 1.5% agarose gel. Densitometric analysis of PCR product bands was carried out by using the Scion Image 1.62 c program. Relative expression levels of examined genes were estimated by normalization to the expression level of control gene, β actin (ACTB). Data obtained with ACTB were used for calculation of P value of gene expression changes in glioblastoma by unpaired t test assuming unequal variance.
Real time PCR was performed with the iCycler iQ5 (BIO RAD, USA). Reaction mixture (20 μl) con tained 2 μl cDNA (quantity equivalent to synthesized on 50 ng of total RNA), 10 μl Maxima™ SYBR Green qPCR Master Mix ("Fermentas") and 10 pmole of each IGF1, IGF2 and IGF1R gene specific primer ( Table 1 ). The amplification procedure of target genes was as follows: initial denaturing step at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 56°C for 15 sec and extension at 72°C for 15 sec. Melting curve analysis was per formed to confirm amplification of single bands. Reaction efficiency was calculated by R package named qpcR package [19] . Gene expression values (relative mRNA levels) were calculated based on the modified ΔΔCq method [20] as ratio of efficiency raised to power Ct of analyzed gene to efficiency increased to power Ct of reference gene (ACTB).
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In GEO repository, IGF1 gene set consists of three different probes corresponded to three nucleotide sequences in GeneBank (AU144912, M29644 and M37484) and represented different regions of IGF1 mRNA. Although the results were little bit different for each probe (Fig. 1) , the average IGF1 gene expres sion level was even 1,5 fold lower in glioblastoma than in anaplastic astrocytoma or human normal brain with P < 0.05 (the significance of differences was calculated using unpaired two tailed t test and assuming unequal variance (Table 3) . Analysis of each DataSet file for each IGF1 probe also did not reveal significant differ As it concerns IGF2 gene, SAGE revealed about 30 fold increased average expression level in glioblas toma as compared to adult normal brain. However, this increasing was not statistically significant (P = 0.293) due to the very high expression levels in two of nine glioblastoma samples, much more than the sam ple population median level. In GEO repository, IGF2 gene set also consists of three different probes corre sponding to nucleotide sequences in GeneBank: M17863, NM_000612 and X07868. In spite of some variations between different probes, the results show mainly that in average the expression level of IGF II gene in glioblastoma is increased slightly as compared to anaplastic astrocytoma or normal brain (Fig. 4 ) and 1.6 fold increasing of average IGF II expression in glioblastoma as compared to human normal brain is statistically significant (Table 3) . Analysis of individual DataSet files for each IGF2 probe showed that glio blastomas can be divided on two subgroups: one group has low expression level of IGF2 gene just like normal brain samples, but other group was characterized by significantly increased expression of IGF2 gene (Fig. 5a ). This division could be seen more distinctly if individual samples of 81 glioblastomas and 23 normal brains, analyzed in GDS1962 file, to arrange accord ing to IGF2 expression level in descending order: approximately one quarter of glioblastoma samples has increased IGF2 expression level while other three quarters of glioblastoma samples have low expression level (Fig. 5b) . These microarray data are in a good concordance with results obtained by SAGE and were supported by real time (Fig. 3 ) and semi quantitative RT PCR (Fig. 6 ).
IGF1 receptor is very well known target for anti cancer therapy [28] . However, SAGE revealed only 1,4 fold not statistically significant increasing of IGF1R expression (P = 0.510) and microarray tech niques showed even 1.2 fold (P = 0.046) decreasing of its expression in glioblastoma as compared to normal brain (Table 3 ). Real time RT PCR (Fig. 3 ) revealed 1.7 fold increasing of IGF1R expression, but the result was not statistically significant (P = 0.545). Thus, it can be concluded that IGF1R expression do not differ significantly in glial tumors and human normal brain. Expression of insulin receptor (IR), which is used alternatively by IGF2 [29] , was decreased in 1.5 fold in glioblastoma according to SAGE and microarray results. At the same time, the expression of IGF2R gene was increased in glioblastoma as compared to normal brain according to SAGE (3.3 fold, P = 0.053) and microarray analysis data (1.9 fold, P < 0.001) ( Table 3) .
Comparison of IGFBP genes expression in glioblas toma and normal brain by SAGE revealed increased expression of all genes in glioblastoma except IGFBP1 (Table 3 ). More than 3 fold upregulation of IGFBP2, IGFBP3, IGFBP4, IGFBP5, and IGFBP7 genes in glio blastoma was statistically significant (P < 0.05) and confirmed by data of microarray analysis, which showed statistically significant increased expression levels also for IGFBPS and IGFBP10 in addition to these five genes. Decreased expression of remained three genes (IGFBP1, IGFBP6 and IGFBP9) in glio blastoma according to the results of microarray analy sis in general were not in contradiction with SAGE results which showed some statistically nonsignificant decrease of the expression for IGFBP1 or increase of the expression for IGFBP6 and IGFBP9 (Table 3) .
Results of the IGFBP genes expression analysis by RT PCR were in a quite good concordance with SAGE and microarray data. Semi quantitative RT PCR confirmed statistically significant increased expression of IGFBP2, IGFBP3, IGFBP4, IGFBP7, IGFBP8, and IGFBP10 genes in glioblastoma (Fig. 6) . Expression of IGFBP5 was increased too, although P = 0.072. RT PCR revealed also increased expres sion of IGFBP1 gene in glioblastoma and this 1,88 fold increase was statistically significant (Table 3) . Unlike RT PCR, SAGE and microarray analysis results showed not statistically significant decrease of IGFBP1 expression level in glioblastoma. Expression of IGFBP6 and IGFBP9 genes was not changed significantly in glioblastoma according to the results of RT PCR and this in general does not contradict to SAGE and microarray analysis, as mentioned above (Table 3) .
So, the expression of seven IGFBP genes (IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP7, IGFBP8, and IGFBP10) was increased in glioblastomas according to three methods used for the analysis. The results for IGFBP6 and IGFBP9 genes differ slightly for three methods, but there were no contrast differences between these results. It is necessary to note that gene expression differences found by microarray analysis were more statistically significant: p values were below the chosen threshold P < 0.05 for all genes analysed except IGFBP1. This may be explained by larger sam ple numbers in both glioblastoma and normal brain groups analysed by this method as compared to SAGE or RT PCR. attractive target for cancer therapy. Various strategies have been used to target components of this system in established animal and human tumor cell lines and in animal models of cancer; some of these strategies may be advancing to clinical use. Among them IGF1 was targeted by different strategies including IGF1 peptide analogues [30] , antisense oligonucleotides [31] and triple helix expressing vectors [32] .
Although increased expression of IGF1, IGF2, IGF1R or combinations thereof have been docu mented in various malignancies, these data show that while a correlation between IGF1/IGF2 expression levels and tumor progression could be consistently documented in some types of cancer (e.g. colorectal, hepatocellular and pancreatic carcinomas), no consis tent correlation was seen in others (e.g. breast cancer) [4] . 
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Taken as a whole, these studies suggest that the IGF1 role in a paracrine and/or autocrine promoting tumor growth may vary depending on the tissue of origin.
Moreover, in some cases, conflicting results were obtained in different studies that analysed the same types of malignant tumors (e.g. gliomas). The refer ences on IGF1 gene expressions in glioblastoma are based on old papers, where authors used mostly slot blot hybridization or immunohistochemistry on com parably small numbers of clinical samples [5] [6] [7] [8] [9] [10] . Immunohistochemical studies themselves are not very convin cing: authors only mention the expression of IGF1 in primary human astrocytomas [6] or write that IGF1 mRNA can be seen in both astrocytoma and non malignant control human brain tissue [7] . The increased level of IGF1 expression was mostly at the margin of glioblastomas and in perivascular zone and so as it was explained by authors [8, 9] , could not be seen when the total RNA from the whole tumor was taken for IGF1 mRNA measurement.
On the other hand, the expression of IGF1 gene in astrocytic tumors was not found when we used SAGE or analysed data from the GEO repository. These data show that IGF1 gene is expressed at a low level in nor mal adult human brain and this level was not increased in glioblastoma. As it was mentioned above, other investigations also did not show the increased IGF1 gene expression in this tumor [9, 10] . Taking into account quite big number of samples and different methods used in present investigation, the results of this study indicate that increasing of IGF1 gene expression may be involved only in the formation of the limited part of astrocytic gliomas. Although the IGF1 was proposed as one of targets for glial tumor therapy and was supposed to become the alternative treatment for human glioblastoma [33] , our results show why the anti IGF1 treatment may not give posi tive results with gliomas, supposing that the develop ment of these tumors is activated by some other way.
In contrast to IGF1, the expression of IGF2 gene is up regulated in glioblastoma although its expression level is relatively low as it was found previously in our work [34] as well as in other publications [35, 36] . Microarray analysis data show clearly the existence of the separate group of the glioblastomas overexpressing IGF2 gene. This is in agreement with the results of Sor oceanu et al. [37] who found that among 165 primary high grade astrocytomas, 13% of glioblastomas and 2% of anaplastic astrocytomas expressed IGF2 mRNA at the levels > 50 fold the sample population median.
Authors found that IGF2 can substitute for EGF to support the growth of glioblastoma derived neuro spheres and growth promoting effects of IGF2were mediated by the IGF1 receptor and phosphoinositide 3 kinase regulatory subunit 3 (PIK3R3), a regulatory subunit of PI3K.
Survey of published data revealed only two old pub lications in which the author reported about the four fold increase of IGF2 receptor, but not IGF1 receptor [38] or 2 to 5 fold higher cellular concentration of IGF2 receptor than the amount of IGF1 receptor [39] . Thus, IGF1 participation in cellular signaling path ways of glioblastoma may be substituted by IGF2 which may also stimulate both main signaling path ways, regulated by the extracellular signal regulated When viewed together, all studies concerning the role of IGFs and IGF1R expression levels per se as indi cators of tumor stage or predicators of disease out come defy simple generalization and may be highly tumor type specific. However as discussed above, the relevance of the IGF axis to cancer progression cannot be fully estimated by analysis of the expression levels of the IGF1R and its ligands only, because activation of the signaling pathway may occur through alternative mechanisms that bypass the requirement for receptor and/or ligand upregulation. activates two signal cascades, regulated by ERK1/2 and AKT and associated with mitogenesis control [41] .
Results of the analysis of IGFBP genes expression in glioblastoma, obtained with three methods, dem onstrate up regulation of the majority IGFBPs in this tumor. Increased expression of IGFBP2 [21, [42] [43] [44] [45] [46] [47] [48] , IGFBP3 [44, 47, 49, 50] , IGFBP4 [21, 49] , IGFBP5 [44, [48] [49] [50] , IGFBP6 [21, 44, 49] , IGFBP7 [51] , and IGFBP8 [44] genes in glioblastoma was reported previ ously in the studies using microarray analysis. It was shown that overexpression of IGFBP5 gene correlates with the histological grade of human diffuse glioma: 83% (58/70) of glioblastomas (WHO Grade IV) were immunopositive for IGFBP5, which was significantly higher than WHO Grade III gliomas (41%, 41/101) or WHO Grade II gliomas (18%, 13/72) (p < 0.001) [52] . Expression of IGFBP1 to IGFBP6 was analysed by PCR in glioblastoma cell lines T98G, A172, 86HG39 and U87MG and expression of IGFBP2 IGFBP6 was found in all cell lines [36] . Higher content of IGFBP1 mRNA in primary gliomas was demonstrated only in one work [53] . Authors found by RT PCR that expression level of IGFBP1 gene did not depend on grade of tumor malignancy.
Produced in tumor cells IGFBPs may stabilize insulin like growth factor (s), IGF1 and/or IGF2, and drive their activation in glial tumors. On the other hand, some of the IGFBPs inhibit IGF actions or may act by a mechanism independent of IGFs, as reviewed by Mohan and Baylink [16] . It was documented that IGFBP1 increased migration of Chinese hamster ovary cells and trophoblast cells and affected apoptosis of breast cancer cells independently of IGF1 by acti EXPRESSION OF GENES BELONGING TO THE IGF SYSTEM 313 vating α5β1 integrin-FAK ILK PI3 K Akt signaling cascade [54] . Function of other inhibitory protein, IGFBP2, could be complex depending on the cell type and cel lular microenvironment. As reviewed by Fukushima and Kataoka [55] , IGFBP2 has been considered as an inhibitory factor of IGF actions, particularly of IGF2, but binding of the IGFBP2/IGF complex to cellular surface proteoglycan may result in concentration of IGFs on the cell surface thus enhancing their actions. Authors supposed, that since binding of IGFs by IGFBP2 has growth and/or migration inhibitory effects, other mechanisms must be taken into account if attempt to find the correlation between overexpres sion of IGFBP2 and malignant phenotypes of glioblas toma and proposed that IGFBP2 exerts influence on stimulation of cell proliferation and/or migration in an IGF independent manner. Other study supported this suggestion and provided definitive evidence that IGFBP2 plays a key role in activation of the AKT pathway and collaborates with K Ras or platelet derived growth factor B (PDGFB) in the development and progression of astrocytoma and oligodendro glioma [56] .
IGFBP3 is known to block IGF action and inhibit cell growth. In addition, it possesses both growth inhibitory and potentiating effects on cells that are independent of IGF action and are mediated through specific IGFBP3 binding proteins/ receptors located at the cell membrane, cytosol, or nuclear compart ments and in the extracellular matrix. Transferrin and type I alpha collagen were characterized as these IGFBP3 binding proteins [57, 58] . IGFBP3 was found among hypoxia induced genes by the comparison of gene expression profiles of the U251 malignant glioma cell line under normoxic and hypoxic conditions, but the role of increased expression of IGFBP3 gene in glioma tumorigenesis is unclear [59] .
It was revealed that IGFBP4, a negative modulator of IGF1, displayed IGF1 independent anti angiogenic effect on glioblastoma cells in response to their treat ment by dibutyryl cyclic AMP (dB cAMP) [60] .
IGFBP5 could also stimulate cell migration through interaction with cell surface heparin sulfate proteoglycans and to determine cell fates by regulating apoptotic molecules (bax, bcl 2) and activating p38 MAP kinase and ERK 1/2 signal transduction path ways [61] .
IGFBP6 is a relatively specific inhibitor of IGF2 actions. Overexpression of IGFBP6 inhibits tumor growth by inducing apoptosis and recently IGFBP6 was listed as a marker for cell senescence because it pro duces growth arrest with features of senescence but with out the expression of cell differentiation markers [62] .
IGFBP7 plays a negative role in the growth of can cer cells, including breast cancer, human prostate can cer, human cervical carcinoma (HeLa), murine embryonic carcinoma (P19), and osteosarcoma (Saos 2) cells [63] . Expression of IGFBP7 has been found to be up regulated in human colorectal cancer and glioma cell lines and down regulated in prostate and breast cancer cells. IGFBP7 is exclusively associ ated with laminin stained glioblastoma vessels but was not observed in the vessels from nonmalignant brain [51] . IGFBP7 regulated glioma LN18 and LN443 cells proliferation and growth but not cell survival and promoted the migration of these cells through regulat ing the AKT (decreased phosphorylation) and ERK1/2 (enhanced phosphorylation) signal trans ductions [64] .
IGFBP8(CTGF), IGFBP9(NOV) and IGFBP10 (CYR61) belong to the family of genes encoding CCN (cysteine rich CYR61/CTGF/nephroblas toma overexpressed gene) proteins which has been shown to play an important role in many processes, including proliferation, migration, adhesion, extracellular matrix regulation, angiogenesis, tumorigenesis, fibro sis, and implantation. CCN proteins share a modular structure and have in their N ter mini four conserved domains with sequence homologies to insulin like growth factor binding proteins (IGFBPs) [65] . Expression of these three genes was analysed by real time PCR in gliomas of different malignancy grades and normal human brain by Xie et al. [66] . Authors found enhanced expression of IGFBP8 (CCN2) in 31 and IGFBP10 (CCN1) in 27 from 40 glioblastomas analysed, while only 7 glioblastomas had high levels of IGFBP9 (CCN3) mRNA. Significant correlation existed between IGFBPS and IGFBP10 mRNA levels with tumor grade and survival of glioblastoma patients, but statistical analysis showed no difference between the clinical and pathological features and expression level of IGFBP9 in gliomas. Results obtained in this work suggest that IGFBP8 and IGFBP10 may play some role in the progression of gliomas, but IGFBP9 is involved neither in their development nor progression. Furthermore, IGFBP9 had antiproliferative activity and suppressed the growth of glioma cells [67] . It was shown that IGFBP8 (CTGF) was associated with oncogenic activities and drug resistance in glioblastoma. Overexpression of IGFBP8 caused the U343 glioblastoma cells to survive for longer than 40 days in serum free medium and resist antitumor drugs including tumor necrosis factor (TNF), TNF related apop tosis inducing ligand, VELCADE (bortezomib, proteasome inhibitor) and temozolomide [68] . Xie et al. [69] demonstrated that IGFBP10 acts as an oncogene through the integrin linked kinase (ILK) to stimulate β catenin TCF/LEF and AKT signaling pathways. Authors showed that forced expression of IGFBP10 in U343 glioblastoma cells accelerated their growth in liquid culture, enhanced their anchorage independent proliferation in soft agar, and significantly increased their ability to form tumors in nude mice.
As a summary, we have shown that IGF1 gene expression is increased only in few cases of glioblas CYTOLOGY AND GENETICS Vol. 45 No. 5 2011 toma but predominantly it is not higher that in normal brain. IGF1 participation in cellular signaling path ways of glioblastoma may be substituted by increasing expression of IGF2 or IGF1R, which may also stimu late both main signaling pathways, regulated by ERK1/2 and AKT. Several other genes with signifi cantly increased expression may also stimulate these pathways in glioblastoma. Up regulated IGFBPs may activate IGF, even if the latters do not increase their expression leading to the anti apoptotic consequences in glial tumors. On the other hand, increased produc tion of some IGFBPs leads to enhance their IGF independent effects which may play an important role in the development of gliomas.
Obtained results highlight the importance of view ing the IGF related proteins as a complex multifacto rial system and show that changes in the expression levels of any one component of the system, in a given malignancy, should be interpreted with caution. Simi lar to the experience with other biology based thera pies, effective targeting of the IGF system may require a customized approach, where tumor profiling guides the selection of the appropriate drugs. As targeting of the IGF family members for anti cancer therapy is rapidly becoming clinical reality, an understanding of this complexity is very timely.
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